News on Medial

Argos Watches raises Rs 6.5 Cr in Angel round

EntrackrEntrackr · 3m ago
Argos Watches raises Rs 6.5 Cr in Angel round
Medial

Argos Watches raises Rs 6.5 Cr in Angel round Indian luxury watch brand Argos Watches has raised Rs 6.5 crore (around $780K) in an angel funding round, valuing the company at Rs 45 crore ($5.4 million) from a group of high-net-worth Indian investors. The proceeds will be used to create new products, build brand awareness, and grow online. Argos aims to double its revenue this year. Founded by Mr. M. Shahiwala, Argos brand offers high-quality, vintage-style automatic and hand-wound watches at affordable prices. It sells its watches only through its website, using a direct-to-consumer model to offer an easy buying experience. Its watches cost between Rs 8,000 and Rs 20,000. Its Apollo series and flagship Olympus watch, a mechanical watch with a power reserve indicator, have gained popularity among Indian watch enthusiasts. As of 2025, Argos remains bootstrapped, with an estimated revenue of around $580,000 annually. The brand plans to launch more models with advanced features while continuing to build its brand through community engagement and digital presence.

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 2d ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.